XBiotech Plunges on Results of Colorectal Cancer Drug Trial - Bloomberg

Bidness ETC

XBiotech Plunges on Results of Colorectal Cancer Drug Trial Bloomberg XBiotech Inc. plunged a record 50 percent after a late-stage study of its lead drug, using an unconventional method to evaluate its cancer-fighting abilities, raised questions about any potential benefit for patients. Rather than the traditional ... Novel Antibody Offers Hope for Patients With Advanced CRCMedscape XBiotech Cancer Drug Survival Claim Falls Apart Under ScrutinyTheStreet.com XBiotech Inc: Here's Why Investors Shouldn't be Fooled by Phase 3 ResultsBidness ETC Insider Monkey (blog) -Seeking Alpha -Zergwatch all 9 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNFUxbGev9V1Z_Je431JovA5Ou-Ilg&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779149900919&ei=8PN7V8n_IdjP3AGvho3gBg&url=http://www.bloomberg.com/news/articles/2016-07-05/xbiotech-plunges-on-results-of-colorectal-cancer-drug-trial
via IFTTT